{
  "docId": "019de073-4472-76ed-a8f3-3d6ae669b88a",
  "docSlug": "6078678dfcf31020360c86ce90f559c0",
  "documentTitle": "BioNTech | Results Presentation Deck | 32 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 32,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The chart uses a logarithmic scale for the y-axis (pVN50 titer).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-4472-76ed-a8f3-3d6ae669b88a/15",
  "deckHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a",
  "deckJsonHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a.json",
  "deckAnchorHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Compared to Monovalent OMI BA.1, BA.4/5 neutralizing titers increase by ~11.3 fold (mono BA.4/5) or ~4.8 fold (bivalent BA.4/5)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d366e6f-5a3f-4787-80d3-7c663532e008",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.85,
        "x": 0.08,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Bar chart showing pVN50 titers for different booster groups against Wildtype, BA.1, BA.2, BA.2.12.1, and BA.4/5 variants.",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c768ff43-0846-48ac-94db-7dc486f7a418",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "N=8 mice Balb/c mice. Mice preimmunized with 2 doses of BNT162b2; boosters given at day 104. Pseudovirus neutralization assay; LOD, Limit of Detection; GMT, geometric mean titers",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33d1081d-3660-4767-b52d-22f5a6a1457a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Omicron BA.4/5 Monovalent and Bivalent Boosters in Mice Substantially Increase Omicron Neutralization Responses to All Tested Omicron Variants",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8cbb974-6121-4f54-8182-e470daefc3f4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "b84dfaab-eb57-41b4-b2b7-eb4a76117854",
      "evidence": "Compared to Monovalent OMI BA.1, BA.4/5 neutralizing titers increase by ~11.3 fold (mono BA.4/5) or ~4.8 fold (bivalent BA.4/5)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 14,
      "beatId": "3e15c075-609e-40f0-bec2-42991fe6e637",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation highlights the challenges posed by Omicron BA.4/5 variants and the need for updated vaccines",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "caf53cc9-d49f-4125-a4b5-522d3d0ef84c",
      "evidence": "The presentation highlights the risks of not updating vaccines and the benefits of BioNTech's solutions",
      "position": 0,
      "objective": "What are the consequences of not adapting to evolving COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}